[U: Now Over $118, On Friday!] Power Alley: Excellent Q2 2025 Results For Gilead -- Raising Top- And Bottom-Line Guidance For The Full Year. Up $3/Sh, In NASDAQ After-Hours Trading...

Well, I am pleased. Over $118 $113, now. Sweet.

To be sure, there will be ups and downs -- over the next 24 months -- but this is a very well-run public life sciences company.

Here's a bit, from Bloomberg reporting:

. . .Gilead Raises Guidance on Robust Demand for Its HIV Treatments

Gilead Sciences Inc. lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and earnings modestly beat analyst expectations.

The company now expects profit excluding some items will be as much as $8.25 a share this year, up from a prior forecast of as much as $8.10. The drugmaker also raised its guidance for annual product sales by about $100 million. . . .

Now you know. Onward, grinning.

नमस्ते